Bristol Myers Squibb Co. has announced long-term data from its closely watched psoriasis pill, deucravacitinib, which it hopes will supplant Amgen Inc.’s blockbuster, Otezla (apremilast), as the main oral therapy for the disease.
Toosonix A/S has launched two trials as it moves to gather data enabling its high-intensity focused ultrasound (HIFU) device to get approval for use in clinical dermatology indications. The company reported on April 19 that the first patients have been treated in a trial of its System One-M device in treating basal cell carcinoma (BCC). Meanwhile, the first patient has been cleared for treatment on April 28 in a study in neurofibromatosis, an inherited condition that causes benign tumors to form on the skin.
New and updated preclinical and clinical data presented by biopharma firms at the American Academy of Dermatology annual meeting, including: Almirall, Amryt, Aslan, Boehringer, Cara, Eli Lilly, Evelo, Incyte, Novartis, Rapt, Regeneron, Senhwa, UCB.
RSS
